TriLink BioTechnologies® Extends Global Support of Covid-19 Vaccine Development into APAC Region with the Chula Vaccine Research Center (Chula VRC), Bangkok

Author's Avatar
Aug 02, 2021

TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA manufacturing process development and its proprietary mRNA capping technology, ushering a much-needed vaccine into economically developing countries